Table 5 Economic analysis: outcomes in a cohort of 1000 births where oxytocin is and is not available in the hospital setting
Scenario | Oxytocin available in hospital setting | Oxytocin not available | ||||
|---|---|---|---|---|---|---|
hospital/community | Oxytocin/Misoprostol | Oxytocin/No treatment | Increment | Misoprostol | No treatment | Increment |
Efficacy | ||||||
PPH | 124 | 146 | −22 | 123 | 160 | −37 |
Severe PPH | 27 | 29 | −2 | 27 | 30 | −3 |
Additional uterotonics | 82 | 88 | −6 | 62 | 72 | −10 |
Blood transfusion | 6 | 9 | −4 | 2 | 8 | −6 |
Safety | ||||||
Shivering | 219 | 89 | 130 | 325 | 108 | 217 |
Fever | 56 | 14 | 42 | 86 | 16 | 70 |
Cost | ||||||
Drugs for prevention | $249 | $87 | $162 | $270 | $0 | $270 |
Treatment of PPH | $2 383 | $2 865 | -$482 | $1 968 | $2 770 | -$803 |
Total Cost | $2 633 | $2 952 | -$320 | $2 238 | $2 770 | -$533 |